Localized and systemic scleroderma show different histological responses to methotrexate therapy

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Pathology

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH779>3.0.CO;2-8PMID 11276011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased number of mast cells accompany enhanced collagen synthesis in linear localized scleroderma

  2004cited by this paper
• Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis.

  1999cited by this paper
• Low-dose methotrexate in the treatment of widespread morphea.

  1998cited by this paper
• Disaccharide analysis of skin glycosaminoglycan in localized scleroderma.

  1997cited by this paper
• The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL-3, IL-4 and IL-8 mRNA in a human mast cell line.

  1997influential reference
• Human epidermal keratinocytes are a source of tenascin-C during wound healing.

  1997cited by this paper
• Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

  1996cited by this paper
• IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts.

  1996cited by this paper
• Nodular Scleroderma: Focally Increased Tenascin Expression Differing from That in the Surrounding Scleroderma Skin

  1995cited by this paper
• Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis.

  1995cited by this paper
• Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments.

  1995cited by this paper
• Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma

  1995cited by this paper
• Presence of N-Unsubstituted Glucosamine Units in Native Heparan Sulfate Revealed by a Monoclonal Antibody (*)

  1995cited by this paper
• Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells.

  1995cited by this paper
• Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues.

  1994cited by this paper
• Connective tissue alterations in systemic sclerosis.

  1994cited by this paper
• TENASCIN EXPRESSION DURING WOUND HEALING IN HUMAN SKIN

  1994cited by this paper
• Demonstration of interleukin 8 in serum samples of patients with localized scleroderma.

  1994cited by this paper
• Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture.

  1993cited by this paper
• Immunohistochemical study of basement membrane reconstruction by an epidermis-dermis recombination experiment using cultured chick embryonic skin: induction of tenascin.

  1992cited by this paper
• Disaccharide analysis of the skin glycosaminoglycans in systemic sclerosis

  1992cited by this paper
• Increased expression of tenascin in the dermis in scleroderma

  1992influential reference
• A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats.

  1992cited by this paper
• Tenascin expression in hyperproliferative skin diseases

  1991cited by this paper
• Production and characterization of a monoclonal antibody against human glomerular heparan sulfate.

  1991cited by this paper
• Tenascin expression in human dermis is related to epidermal proliferation.

  1991cited by this paper
• Methotrexate: mechanism of action in rheumatoid arthritis.

  1990cited by this paper
• Deposition of extracellular matrix along the pathways of migrating fibroblasts

  1990cited by this paper
• Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts.

  1989cited by this paper
• Localized scleroderma.

  1989cited by this paper
• Localized scleroderma.

  1989cited by this paper
• Mast cell changes in a case of rapidly progressive scleroderma-ultrastructural analysis.

  1989cited by this paper
• Systemic scleroderma: clinical and pathophysiologic aspects

  1988cited by this paper
• Mast cells and fibrosis.

  1987cited by this paper
• Mast cell numbers in diffuse scleroderma.

  1987cited by this paper
• Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?

  1985cited by this paper
• The pharmacology and clinical use of methotrexate.

  1983cited by this paper
• Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

  1969cited by this paper

• An overview of the role of chemokine CX3CL1 (Fractalkine) and CX3C chemokine receptor 1 in systemic sclerosis

  2024cites this paper
• Traditional Chinese Medicine Integrated Responsive Microneedles for Systemic Sclerosis Treatment

  2023cites this paper
• Evaluation and Treatment of Pediatric Localized Scleroderma: Pearls and Updates

  2021cites this paper
• Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis

  2020cites this paper
• Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis Single centre experience

  2020cites this paper
• Localized scleroderma and eosinophilic fasciitis: clinical and immunological monitoring and treatment

  2019cites this paper
• Magnetic Resonance Imaging Evaluation in Patients with Linear Morphea Treated with Methotrexate and High-Dose Corticosteroid

  2018cites this paper
• Morphea and Eosinophilic Fasciitis: An Update

  2017cites this paper
• Localized scleroderma: a review

  2016cites this paper
• Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach.

  2013cites this paper
• COMPARISON OF HYDROXYCHLOROQUINE AND METHOTREXATE IN TTREATMENT OF PATIENTS WITH LOCALIZED SCLERODERMA

  2013cites this paper
• Localized Forms of Scleroderma

  2012cites this paper
• Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.

  2011cites this paper
• Pathogenesis and treatment modalities of localized scleroderma.

  2010cites this paper
• The ‘Connective Tissue Diseases’

  2010cites this paper
• Methotrexate for sclerotic skin disorders: no evidence for effectiveness

  2009cites this paper
• the US multicenter pilot study of cell transplantation for severe systemic sclerosis: long-term follow-up High-dose immunosuppressive therapy and autologous hematopoietic

  2007cites this paper
• Evaluation of oral methotrexate in the treatment of systemic sclerosis

  2007cites this paper
• High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

  2007cites this paper
• Treatment of pediatric localized scleroderma with methotrexate.

  2006cites this paper
• Esclerodermia lineal Estudio de 55 pacientes. Análisis de 5 fenotipos cutáneos

  2005cites this paper
• Oral effects of low-dose methotrexate treatment.

  2005cites this paper
• Collagen vascular diseases.

  2004cites this paper
• The Use of Streptolysin O for the Treatment of Scars, Adhesions and Fibrosis: Initial Investigations Using Murine Models of Scleroderma

  2004cites this paper
• What Is Nodular-Keloidal Scleroderma?

  2003cites this paper
• Scleroderma-like cutaneous syndromes

  2002cites this paper